Venous thromboembolism risk up with cisplatin-based chemo

Venous thromboembolism risk up with cisplatin-based chemo
Patients with advanced solid tumors receiving cisplatin-based chemotherapy regimens have a significantly higher risk of having a venous thromboembolic event compared with those who do not receive a cisplatin-based regimen, according to research published online Nov. 13 in the Journal of Clinical Oncology.

(HealthDay)—Patients with advanced solid tumors receiving cisplatin-based chemotherapy regimens have a significantly higher risk of having a venous thromboembolic event (VTE) compared with those who do not receive a cisplatin-based regimen, according to research published online Nov. 13 in the Journal of Clinical Oncology.

To evaluate the incidence and risk of VTEs associated with cisplatin-based chemotherapy, Sonia Seng, M.D., of the Southcoast Centers for Cancer Care in Fairhaven, Mass., and colleagues conducted a systematic review and meta-analysis of 38 from 1990 to 2010 involving 8,216 patients with various advanced solid tumors.

The researchers found that the incidence of VTEs in patients treated with cisplatin-based chemotherapy was 1.92 percent, compared with 0.79 percent in patients who did not receive cisplatin-based regimens. Cisplatin-based therapy was associated with significantly increased risk of a VTE (relative risk [RR], 1.67). Patients receiving a weekly equivalent cisplatin dose greater than 30 mg/m² had the highest risk (RR, 2.71), and increased risks were also noted for patients in trials during 2001 to 2010 (RR, 1.72).

"We observed a 1.67-fold increase in the risk of VTEs with cisplatin as compared with non-cisplatin-based chemotherapy," the authors write. "Given the morbidity and mortality associated with VTEs in patients with cancer, our study adds further support to calls for prospective trials of -based chemotherapy administered with prophylactic anticoagulation."

Several authors disclosed to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.